C-Bridge Capital

C-Bridge Capital is a private equity firm that specializes in facilitating cross-border investments and strategic alliances, primarily focusing on opportunities in the United States, China, and Israel. The company leverages its extensive network and deep industry knowledge to help clients navigate complex international markets, driving growth and development through targeted investments. C-Bridge Capital is actively involved in monitoring and safeguarding its clients' interests to ensure optimal returns on their investments. The firm emphasizes collaboration and partnership, aiming to unlock value across various sectors while fostering the development of innovative solutions.

Wei Fu

Founder and CEO

Mengjiao Jiang

Partner

Shen M.D., Christopher T.

Managing Director

19 past transactions

Yaneng Biotechnology

Venture Round in 2022
Yaneng Biotechnology produces a gene diagnostic chip technology platform. They provide cervical cancer screening and hereditary disease diagnostics, such as pre pregnancy and prenatal diagnosis and screening tests, and automatic nucleic acid extractor. They also provide resarch and development services.

RVAC Medicines

Series B in 2022
RVAC Medicines is an mRNA platform company with a pipeline of novel products covering a wide range of disease areas. The company is building a pipeline of novel mRNA vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. It's cutting-edge GMP manufacturing facilities that will advance its platform technologies through in-house research and development and external partnerships, enabling the production of cutting-edge mRNA and nucleic acid delivery technologies. RVAC Medicines was founded in 2021 and is based in Singapore.

LakeShore Biopharma

Venture Round in 2022
LakeShore Biopharma is a global, fully integrated medical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.

AffaMed Therapeutics

Series B in 2021
AffaMed Therapeutics is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products.

Nuance Biotech

Series D in 2020
Nuance Biotech is a pharmaceutical company Based In China.

GrayBug

Series C in 2019
GrayBug is a pharmaceutical company that develops transformative medicines for ocular diseases. They also develop therapies for inflammatory diseases with unmet needs. Their proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury.

I-Mab Biopharma

Series C in 2018
I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. .

Nuance Biotech

Series B in 2018
Nuance Biotech is a pharmaceutical company Based In China.

CMLabs

Series C in 2018
The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.

CMAB BioPharm

Series B in 2018
CMAB BioPharm is a Biopharmaceutical Service Firm. Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.

CMAB BioPharm

Series A in 2018
CMAB BioPharm is a Biopharmaceutical Service Firm. Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.

I-Mab Biopharma

Series B in 2017
I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. .

Anrei Medical

Venture Round in 2017
Anrei medical (hz)co.,ltd, a US wholly owned and FDA registered enterprise, was founded 2006. The company has been developing disposable medical devices for use in a variety of minimally invasive procedures since inception and is a high-tech company vertically integrated in the areas of research and development, manufacturing, distribution and customer service.

Ascletis

Series B in 2017
Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China's capital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases.

I-Mab Biopharma

Series A in 2016
I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. .

FitSAMO

Series A in 2016
FitSAMO is an orthopaedic surgical equipment supplier.

Ascletis

Series B in 2015
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a direct-acting anti-viral agent for the treatment of hepatitis C virus (HCV); Pegasys, a pegylated interferon for Hepatitis B and C virus; and Ravidasvir, a pan-genotypic NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B infection; ASC40, a Phase II-ready fatty acid synthase inhibitor for the treatment of non-alcoholic steatohepatitis (NASH); and ASC41, an oral THR-ß agonist for the treatment of NASH. The company’s products also comprise ASC09, a protease inhibitor that has completed Phase IIA clinical trial to treat human immunodeficiency virus type-1 infections; ASC06, which has completed Phase I clinical trial for treating liver cancer; and ASC21, a HCV NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of hepatitis B virus and NASH. The company was incorporated in 2014 and is headquartered in Hangzhou, the People’s Republic of China.

FitSAMO

Angel Round in 2015
FitSAMO is an orthopaedic surgical equipment supplier.

Clarus Therapeutics

Venture Round in 2014
Clarus Therapeutics is a biopharmaceutical company that develops androgen-based medicines for men and women. It offers OriTex, a proprietary oral testosterone product for use in men with low testosterone levels.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.